Table 1.
Patient disposition and baseline characteristics
| Placebo (n = 10) | Canagliflozin | Total (N = 61) | ||||
|---|---|---|---|---|---|---|
| 25 mg (n = 12) | 100 mg (n = 12) | 200 mg (n = 14) | 400 mg (n = 13) | |||
| Gender, n (%) | ||||||
| Male | 8 (80) | 8 (66.7) | 12 (100) | 13 (92.9) | 9 (69.2) | 50 (82.0) |
| Female | 2 (20) | 4 (33.3) | 0 (0) | 1 (7.1) | 4 (30.8) | 11 (18.0) |
| Mean (SD) | ||||||
| Age, years | 57.6 (6.3) | 49.0 (10.6) | 52.1 (7.6) | 56.2 (8.6) | 56.5 (8.2) | 54.3 (8.8) |
| Weight, kg | 69.73 (14.08) | 74.24 (11.04) | 73.44 (11.07) | 63.67 (13.62) | 73.88 (10.18) | 70.84 (12.38) |
| BMI, kg/m2 | 25.75 (3.37) | 26.41 (2.39) | 25.25 (2.40) | 23.20 (4.03) | 27.44 (3.13) | 25.56 (3.39) |
| FPG, mg/dL | 184.9 (35.8) | 172.2 (19.2) | 162.5 (20.4) | 163.4 (14.3) | 170.9 (27.2) | 170.1 (24.3) |
| HbA1c, % | 8.91 (1.16) | 9.11 (0.85) | 8.28 (0.85) | 8.51 (0.82) | 8.58 (0.75) | 8.66 (0.90) |
FPG: 1 mg/dL = 0.0555 mmol/L
BMI body mass index, FPG fasting plasma glucose, SD standard deviation